Glioblastomas
New Glioblastomas Study Findings Have Been Reported by Researchers at Center for Neuro-Oncology
Published in Drug Week, November 4th, 2011
2011 NOV 4 -- Data detailed in "Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure" have been presented. "There is no effective treatment for recurrent glioblastoma (GBM) after bevacizumab failure. Putative mechanisms of resistance to bevacizumab include increased pericyte coverage, mediated partly by platelet-derived growth factor receptor (PDGFR) signaling, and an infiltrative tumor growth pattern potentially dependent on SRC," scientists in Boston, Massachusetts report.
"We explored the efficacy of dasatinib, a SRC, BCR-ABL, c-KIT, EPHA2, and PDGFRß inhibitor, in patients with recurrent GBM after bevacizumab...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2011-11-04)
More Articles from Drug Week
- Electrophoresis
Data from University of Malaya Provide New Insights into Electrophoresis - Drug Abuse
Dr. Drew Pinsky Joins National Association of School Nurses to Launch School Tool Kit Addressing Teen Prescription Drug Abuse - Heparin Therapy
Findings from Case Western Reserve University Broaden Understanding of Heparin Therapy - Drug Abuse
Florida Launches Powerful Tool Keeping Patients Safe from Drug Interactions and Prescription Abuse - Molecular Medicine
Hebrew University Details Research in Molecular Medicine - Mental Health
How to scale up mental health care: As few as 1 in 50 people with mental health problems have access to treatment in developing countries, compared with 1 in 3 in wealthy nations - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
